Where to Begin Take the Quiz Learn (all pillars)

The Pillars

Practice Science The Root Member Stories What We Reject The Mycelium
Browse Everything FAQ Dictionary Manifesto
Connect Contact

The Science

Microdosing for Depression and Anxiety: What the Research Shows

A research-backed look at what the published science actually shows about microdosing for depression and anxiety — the major studies, the limits of the data, and what the field still does not know.

By The Microdose Movement ·

If you have read anything about psilocybin in the past decade, you have probably encountered a confident claim that the science is settled and the mushroom is the next antidepressant. If you have read anything from the skeptics, you have probably encountered an equally confident claim that microdosing is mostly placebo and the headlines are overblown. Both claims are wrong in different directions.

The actual research on psilocybin for depression and anxiety is real, growing, and more interesting than either side of the debate usually presents. This article walks through the most important studies, what they actually found, where the evidence is strongest, and where the honest field still says “we don’t know yet.”

The two halves of the research

Before diving into specific studies, it helps to understand that the research splits into two distinct halves that get conflated in most popular coverage.

Half one: full-dose psilocybin for depression in clinical settings. This is the research that has produced the dramatic headlines. Patients receive 20–25mg of psilocybin in a structured therapy session, with trained guides, in a controlled environment, with integration sessions before and after. The doses are full perceptual doses — patients have a real psychedelic experience. This work is being done at Johns Hopkins, Imperial College London, NYU, the Usona Institute, and several other centers. The published results are strong.

Half two: microdosing — sub-perceptual doses, taken self-directed, often without a clinical setting. This is what most people in the wellness world are actually doing. The research base for this is much smaller and more mixed. The studies that exist are recent, often small, and frequently methodologically harder because microdoses are deliberately subtle and easily confused with placebo.

Both halves matter. They tell different stories. Most popular articles blur them together and give microdosing credit for the strength of the full-dose research. The honest version separates them.

The full-dose depression research

The most influential studies in the modern field are full-dose, not microdose. They are worth knowing because they establish the underlying clinical case for psilocybin even if you are interested in the smaller, gentler practice.

The 2016 Carhart-Harris open-label study

The first major modern study of psilocybin for treatment-resistant depression was published in The Lancet Psychiatry in 2016 by Robin Carhart-Harris and colleagues at Imperial College London. Twelve patients with depression that had failed multiple conventional treatments received two psilocybin sessions. The study was open-label and uncontrolled — methodologically modest by modern standards.

The findings were striking anyway. All twelve patients showed reduced depressive symptoms one week after the sessions. Eight showed clinically significant improvement at three months. Five were in remission at six months. None of these patients had responded meaningfully to standard treatments before. The paper was the proof of concept that justified the larger trials that followed.

The 2020 Davis JAMA Psychiatry trial

In 2020, Alan Davis and colleagues at Johns Hopkins published the first randomized, waiting-list-controlled trial of psilocybin-assisted therapy for major depressive disorder in JAMA Psychiatry. Twenty-four adults with major depression received two psilocybin sessions plus 11 hours of supportive therapy. A waiting-list control group received the treatment after a delay.

The results: at week one and week four after the second session, the psilocybin group showed clinically significant reductions in depression scores. The effect size was large by clinical trial standards (Cohen’s d > 2.0 at week 4) — substantially larger than typical SSRI trial effect sizes.

The study had methodological limitations (small sample, open-label after randomization, waiting-list rather than active placebo control), but it was the first formal randomized trial of psilocybin for depression in a major journal in the modern era.

The 2021 Carhart-Harris NEJM head-to-head study

The most consequential single study was published in The New England Journal of Medicine in 2021. Carhart-Harris and colleagues compared psilocybin to escitalopram (Lexapro) in 59 patients with moderate-to-severe major depression over six weeks. The design was unusually rigorous: half the patients received two doses of psilocybin (25mg) plus daily placebo capsules, half received daily escitalopram plus two psilocybin-shaped placebo doses. Neither patients nor evaluators knew which group anyone was in.

The findings:

This study is the closest thing the field has to a phase II clinical trial of psilocybin as a depression treatment. It established that psilocybin is at least competitive with one of the most-prescribed antidepressants in the world, with a different side effect profile and a different time course.

The 2022 Goodwin Phase 2b trial

A larger Phase 2b trial conducted by COMPASS Pathways and published in NEJM in 2022 enrolled 233 patients with treatment-resistant depression. Patients received a single dose of psilocybin at 25mg, 10mg, or 1mg (the 1mg dose serving as a low-dose comparator). The 25mg group showed significantly greater reduction in depression scores at three weeks than the 1mg group, with about a third of patients achieving response criteria. The 10mg group showed an intermediate effect.

This was the largest psilocybin-for-depression trial published to date and provided the strongest dose-response evidence so far.

What the full-dose research collectively shows

Aggregating across the studies above and several smaller trials, the picture looks like this:

This is real evidence. It is also evidence specifically about full doses given in clinical settings with therapy, not about microdoses given at home.

The microdose research is much smaller and more mixed

The published research on microdosing specifically is younger and harder to interpret. A few studies are worth knowing.

The Polito and Stevenson 2019 longitudinal study

Vince Polito and Richard Stevenson at Macquarie University tracked 98 people who were starting their own microdosing practice. Participants self-reported on a battery of psychological measures over six weeks. The microdosing group showed small but statistically significant improvements in measures of depression, neuroticism, and absorption (a measure of cognitive engagement). The effects were modest. The study had no formal placebo control because the microdosers were self-directed.

The Anderson 2019 cross-sectional survey

Thomas Anderson and colleagues at the University of Toronto compared 278 microdosers to 555 non-microdosers using standard mental health measures. Microdosers reported lower depression and stress scores than non-microdosers, and higher wisdom and creativity scores. The study could not establish causation — microdosers might already be a different population — but the size of the differences was meaningful.

The Szigeti 2021 self-blinded citizen science study

The most methodologically rigorous microdosing study to date was conducted by Balazs Szigeti and colleagues at Imperial College London in 2021. The study used a creative self-blinding design: participants prepared their own dose capsules in opaque envelopes, some containing real psilocybin and some placebo, and tracked outcomes without knowing which they were taking on which day.

The result: the microdosing group and the placebo group both reported substantial improvements in mood and well-being over four weeks. The improvements in the active microdose group were not significantly different from the improvements in the placebo group. The authors concluded that much of the felt benefit of microdosing may be driven by expectation effects rather than direct pharmacological action.

This finding was uncomfortable for the microdosing community and is worth taking seriously. It suggests that the placebo contribution to microdosing’s reported benefits is large.

The 2022 Cavanna self-blinding follow-up

A follow-up self-blinding study by Federico Cavanna and colleagues in 2022 partially complicated the Szigeti picture. Their study found that microdoses produced measurable changes in mood ratings and a specific reduction in negative emotion that exceeded placebo effects, though the magnitude was smaller than enthusiast claims.

The Polito 2023 placebo-controlled trial

A 2023 placebo-controlled trial of microdosing by Polito and colleagues — testing very low doses of LSD rather than psilocybin — found small cognitive benefits but no significant mood improvements over placebo. The study suggests that even when microdosing produces measurable effects, they may not be large enough to drive the dramatic mood changes that anecdotal reports suggest.

What this collectively means

The honest summary, as of 2026, is roughly this:

Full-dose psilocybin in clinical settings produces substantial, replicable antidepressant effects that exceed placebo and are at least competitive with SSRIs. The evidence is now strong enough that psilocybin-assisted therapy for depression has FDA breakthrough therapy designation and is in late-stage clinical trials.

Microdosing produces effects that are real but smaller, more variable, and harder to separate from placebo than the full-dose effects. The most rigorous studies suggest expectation effects account for much of the felt benefit. The studies that have found pharmacological effects beyond placebo have generally found smaller magnitudes than enthusiast claims.

This does not mean microdosing is “just placebo.” Placebo effects are real biological phenomena that produce measurable benefits in the people who experience them. The question of whether microdosing “works” is partly a question of how you define working. If a practice consistently improves mood, sleep, and well-being for the person doing it — even if part of that improvement is expectation-driven — that may still be valuable. But the framing matters. Calling microdosing “as effective as antidepressants” overstates what the data shows. Calling it “useless” understates it.

The integration practices around the dose probably matter more than the dose itself. This is consistent with what the full-dose research has found: the size of the psychedelic experience and the quality of the integration work predict outcomes more strongly than the pharmacological details. For microdosing, this suggests that the practice elements — journaling, intention setting, integration days — may carry as much of the benefit as the molecule.

What the science says about anxiety specifically

Anxiety has been studied somewhat less than depression in the modern psychedelic literature, but several findings are worth noting.

The 2016 Griffiths Johns Hopkins study of psilocybin for cancer-related anxiety and depression found that a single high dose produced significant reductions in anxiety and depression that persisted for at least six months in the majority of patients. This is one of the most enduring effect sizes in modern psychiatry and remains a key reference point.

The Imperial College and Johns Hopkins teams have both reported that anxiety reductions tend to track with depression reductions in their broader trials — patients who improve on depression measures usually also improve on anxiety measures.

Microdose-specific anxiety research is more limited. The Polito and Anderson studies referenced above include anxiety measures and report modest improvements. The larger Szigeti self-blinded study did not separate anxiety from general well-being in its primary analysis.

The honest summary on anxiety: full-dose psilocybin in clinical settings produces strong, lasting anxiety reductions in well-studied populations (especially cancer patients). Microdose-specific anxiety research is smaller and produces more modest effects.

What we still do not know

Frequently Asked Questions

Does microdosing actually treat depression?

Full-dose psilocybin in clinical settings produces meaningful antidepressant effects in well-controlled trials. Microdose-specific research is smaller and more mixed, with significant placebo contribution and modest pharmacological effects. The honest answer is that microdosing may help some people with depression, the effects are smaller and less reliable than full-dose research suggests, and the evidence is not yet strong enough to call it a treatment in the clinical sense.

What’s the strongest single study on psilocybin and depression?

The 2021 Carhart-Harris head-to-head trial in The New England Journal of Medicine comparing psilocybin to escitalopram is the most methodologically rigorous and widely cited modern study. It established that psilocybin is at least competitive with one of the most-prescribed SSRIs in the world.

Is microdosing as effective as SSRIs?

The full-dose research suggests psilocybin-assisted therapy is at least competitive with SSRIs in head-to-head trials. The microdose-specific research has not been compared to SSRIs in formal trials. Claims that microdosing is “as effective as antidepressants” are not supported by current data.

What about anxiety specifically?

Full-dose psilocybin produces strong, lasting anxiety reductions in clinical trials, especially in cancer patients. Microdose-specific anxiety research is more limited and shows smaller effects, partly overlapping with general well-being improvements.

Should I use microdosing instead of my antidepressant?

Not without medical guidance. Most people on long-term SSRIs feel little from a microdose because of receptor downregulation, and stopping antidepressants cold turkey is dangerous. The decision about whether and how to taper off conventional treatment should involve a knowledgeable practitioner.

Sources and Further Reading

The Microdose Movement is an educational community, not a medical provider. Nothing in this article is medical advice. If you are in crisis, contact your local emergency services or a crisis helpline.